|  |  |  |
| --- | --- | --- |
| 09-82918_logo_E_RGB | **International Narcotics Control Board** | **FORM C** |

**ANNUAL STATISTICS OF PRODUCTION, MANUFACTURE,**

**CONSUMPTION, STOCKS AND SEIZURES OF NARCOTIC DRUGS**

**Single Convention on Narcotic Drugs of 1961: articles 1, 2, 13, 20 and 27**

**1972 Protocol amending the Single Convention on Narcotic Drugs of 1961: articles 1 and 10**

|  |  |  |  |
| --- | --- | --- | --- |
| **Country or territory:** |  | **Date:** |  |
| **Competent office:** |  | | |
| **Responsible officer’s name:** |  | **Signature:** |  |
| **Title or function:** |  | | |
| **Telephone number(s):** |  | **E-mail:** |  |
| **Fax number(s):** |  | **Calendar year :** |  |

**Remarks**

|  |
| --- |
|  |

The present form should be completed as soon as possible and not later than 30 June of the year following the year to which the statistical data relate. The form can be downloaded from the INCB website. Once completed, the form should be sent in a single copy to:

International Narcotics Control Board

**Vienna International Centre**

**P.O. Box 500   
1400 Vienna  
Austria**

**Telephone: (+43-1) 26060-4277 Facsimile: (+43-1) 26060-5867/5868**

**E-mail:** [**secretariat@incb.org**](mailto:secretariat@incb.org)**, narcotics@incb.org Website:** [**http://www.incb.org/**](http://www.incb.org/)

Please also consider submitting this form in XML format by e-mail

INSTRUCTIONS

General

1. This form is divided into four parts:

Part I: Statistical data on manufacture, consumption, utilization and stocks of narcotic drugs;

Part II: Statistical data on the utilization of narcotic drugs for the manufacture of other substances;

Part III: Statistical data on the licit cultivation of the opium poppy, the cannabis plant and the coca bush and the licit production of opium and poppy straw, cannabis and coca leaves;

Part IV: Statistical data on seizures of narcotic drugs and seizures of pharmaceutical products containing narcotic drugs.

2. In order to ensure the accurate completion of this form pursuant to the provisions of article 1 of the Single Convention on Narcotic Drugs of 1961, the following definitions should be borne in mind:

*(a)* “Consumption” means the act of supplying a narcotic drug to any person or enterprise for retail distribution, medical use or scientific research;

*(b)* “Drug” means any of the substances included in Schedules I or II of the 1961 Convention, whether natural or synthetic, and thus subject to specific control measures under the Convention;

*(c)* “Manufacture” means all processes, other than production (see the definition below), by which drugs may be obtained, and includes refining and the transformation of drugs into other drugs;

*(d)* “Preparation” means any mixture, solid or liquid, subject to international control owing to the fact that it contains a drug under international control. Preparations listed in Schedule III of the 1961 Convention are exempted from some control measures;

*(e)* “Production” means the separation of opium, coca leaves, cannabis and cannabis resin from the plants from which they are obtained;

*(f)* “Stocks” means the amounts of drugs held in a country or territory for domestic consumption, manufacture of other drugs, or export;

*(g)* “Special stocks” means the amounts of drugs held by the Government of a country or territory for special government purposes and to meet exceptional circumstances.

3. All drugs and preparations are listed in the List of Narcotic Drugs under International Control (“Yellow List”), a supplement to the statistical forms on narcotic drugs published on the INCB website (http://www.incb.org/incb/en/narcotic-drugs/Yellowlist\_Forms/yellow-list.html). Poppy straw produced from varieties of opium poppy rich in morphine is referred to as “poppy straw (M)”. Poppy straw produced from varieties of opium poppy rich in thebaine is referred to as “poppy straw (T)”. Poppy straw produced from varieties of opium poppy rich in codeine is referred to as “poppy straw (C)”. Concentrate of poppy straw containing morphine as the main alkaloid is referred to as “concentrate of poppy straw (M)”. Concentrate of poppy straw containing thebaine as the main alkaloid is referred to as “concentrate of poppy straw (T)”. Concentrate of poppy straw containing oripavine as the main alkaloid is referred to as “concentrate of poppy straw (O)”. Concentrate of poppy straw containing codeine as the main alkaloid is referred to as “concentrate of poppy straw (C)”.

4. Amounts reported in the present form should be expressed in terms of the pure anhydrous drug content of the respective quantities of the crude drug, refined drug, base, salt or preparation, other than those listed in Schedule III of the 1961 Convention. All figures reported should reflect the net quantity involved and should be expressed in kilograms and grams (using three digits to indicate grams), or, in the case of fentanyl, its principal analogues, etorphine and piritramide, in grams and milligrams (using three digits to indicate milligrams). Decimal points or commas should not be used. The weight of packaging or containers (such as cases, boxes, wrappers, bottles, tubes or ampoules) should not be included.

5. Tables with the conversion factors for obtaining the pure anhydrous base drug content of esters, ethers and salts are provided in part 4, table 1, of the “Yellow List”. The relevant criteria and conversion factors for tinctures and extracts of opium, coca leaf and cannabis are included in part 4, table 2 of the “Yellow List”.

6. With respect to poppy straw and concentrate of poppy straw, the gross weight of the materials and the quantities of anhydrous morphine alkaloid (AMA), anhydrous codeine alkaloid (ACA), anhydrous thebaine alkaloid (ATA) and anhydrous oripavine alkaloid (AOA) contained in those materials are to be reported.

**Part I**

7. Part I is divided into two sections:

**Part I.A** is to be filled out by all Governments, even if no manufacture of narcotic drugs takes place in the country or territory under their jurisdiction (in which case column 1 of this table should be left blank; however, data on consumption, utilization for the manufacture of Schedule III preparations and stocks should be furnished);

**Part I.B** is reserved for Governments of countries or territories that manufacture, utilize or keep stocks of concentrate of poppy straw.

8. Drugs listed in part I.A have been subdivided into two groups. Those substances that should be reported to the International Narcotics Control Board in kilograms and grams are in the first group, and those substances that are to be reported in grams and milligrams are in the second group. The substances of the first group are listed in alphabetical order, while the substances of the second group follow only partly an alphabetical ranking, as the listing starts with fentanyl and its principal analogues, followed by etorphine and piritramide.

9. Parts I.A and I.B are organized in seven and six numbered columns respectively. As column 4 of part I.A is not contained in part I.B, the columns in that part I.B have been renumbered, although the header and information requested remain the same:

**Column 1**: The quantities of drugs manufactured during the year in question should be reported in this column. The data entered in column 1 should reflect an aggregate figure of the data entered in column 4 of parts II.A and II.B;

**Column 2**: The substances for which data are requested are listed in this column;

**Column 3**: Data on the consumption of each narcotic drug during the year in question should be reported in this column;

**Column 4**: The quantities of drugs utilized for the manufacture of Schedule III preparations should be reported only in this column; it is therefore not applicable to substances not listed in Schedule III (this column does not apply to   
table I.B);

**Column 5**: Data on stocks held as at 31 December of the year in question should be reported in this column (column 4 in table I.B);

**Column 6**: The amounts procured for and/or withdrawn from special stocks should be reported in this column. Whether the amount has been procured (P) or withdrawn (W) will have to be clearly indicated by adding the appropriate letter next to each amount reported or by including the relevant information in the space provided for remarks on the cover page (column 5 in table I.B);

**Column 7**: Data on losses and destructions during the process of manufacture and wholesale distribution of narcotic drugs should be reported in this column. Losses and destructions should include those occurring during manufacture of raw materials, manufacture of preparations and industrial research and development. Data referring to the destruction of obsolete materials or preparations should also be included (column 6 in table I.B).

**Part II**

10. Part II is reserved for Governments of countries or territories that utilize narcotic drugs to manufacture other substances. It is divided into two sections, II.A and II.B, and is presented in four numbered columns.

**Part II.A**, page 8 lists the raw materials, i.e. opium, the three varieties of poppy straw (M, T and C) to be utilized for the manufacture of the main narcotic drugs, and any of the four varieties of the intermediate raw material concentrate of poppy straw (CPS (M), CPS (T), CPS (O) and CPS (C)); page 9 lists those four varieties of CPS either obtained from poppy straw or directly imported, to be utilized for the manufacture of principal narcotic drugs.

**Part II.B** lists the narcotic drugs most commonly obtained from the raw materials mentioned in part II.A or directly imported, and to be utilized for the conversion into other substances for final use (including those not controlled by the 1961 Single Convention).

11. The four columns in parts II. A and II.B list the substances and their quantities used as starting material to manufacture other narcotic drugs (**columns 1 and 2**) and list the substances and their quantities obtained from the conversion processes (**columns 3 and 4**).

At the bottom of part II.B, an empty space is provided to report other narcotic drugs and their quantities used for the manufacture of other substances to be reported along with their quantities.

**Part III**

12. Part III is divided into three sections:

**Part III.A** is reserved for Governments that authorize the cultivation of opium poppy. It contains two columns for the entry of statistical data. **Column 1** should be used for data on the area under cultivation (in hectares), including the total area sown and the total area actually harvested, and **column 2** should be used for data on the total quantity of substances listed in the last column to the right (opium and/or poppy straw), obtained from the total area harvested. Quantities in column 2 should all be entered in kilograms; the quantity of opium produced should be reported in terms of 90-per-cent consistency (10-per-cent moisture content).

**Part III.B** is reserved for Governments that authorize the cultivation of the cannabis plant for the production of cannabis for medical and/or scientific purposes. Statistical data on these areas of production should all be reported in hectares and the quantities of cannabis produced should all be reported in kilograms;

**Part III.C** is reserved for Governments that authorize the cultivation of the coca bush for the production of coca leaves. Statistical data on these areas of production should all be reported in hectares and the quantities of coca leaves produced should all be reported in kilograms.

**Part IV**

13. Part IV on seizures is divided into two sections:

**Part IV.A** is to be filled out by all Governments whenever narcotic drugs (excluding pharmaceutical products) have been seized, destroyed, used for licit purposes and/or taken over by Governments for special purposes during the year in question. Quantities pending disposal should also be indicated; the figures in columns 2 to 4 may also include any quantities that were seized in previous years but have been disposed of only during the year to which the present form refers to.

**Part IV.B** is to be filled out by all Governments whenever pharmaceutical products containing narcotic drugs have been seized. The substance and the pharmaceutical form and content of the active ingredient per unit should be specified. Pharmaceutical products seized containing other narcotic drugs than the ones listed have to be reported as well, and their narcotic drug content specified.

**Additional important remarks**

All Governments of countries and territories, even those that are not producers and/or manufacturers of narcotic drugs, are to fill in and submit this form. As all countries import controlled narcotic drugs to satisfy the medical needs of their population; **it is imperative that data on consumption and/or stocks of imported substances be reported to the Board in part I, columns 2 and 4, respectively.**

When completing part I of the present form, only the quantities of drugs used to manufacture preparations included in Schedule III of the   
1961 Convention should be reported to the Board (column 3). **However, the available quantities of Schedule III preparations (finished preparations) obtained from any starting material and consumed and/or held in stocks as preparations should not be reported. These quantities of Schedule III preparations should also in no way be added to the quantities of pure base drugs reported as having been manufactured, consumed or stocked.**

If parties deem it appropriate to furnish any information on Schedule III preparations, then that information should be clearly provided in the remarks box on the cover page only.

**Data on seizures** **in part IV in this form** **should be compiled and submitted by the competent authorities** of Governments of countries or territories, based on information and figures provided to them by the appropriate national law enforcement institutions, such as police, customs or others as prescribed in article 20 paragraph (e) of the 1961 Convention.

**Note:** Specific guidelines for the preparation of this statistical Form C with detailed background explanations and practical examples are to be found in part III, section IV, of the training material on the INCB website (https://www.incb.org/documents/Narcotic-Drugs/Training-Materials/English/PART\_III\_English.pdf).

It should, however, be noted that the training material is updated on an on-going basis and is therefore subject to change; whenever available, an updated edition will be published on the INCB website.

## PART I.A

Page 5 (Form C)

(For all Governments)

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1 | | 2 | 3 | | 4 | | 5 | | 6 | | | 7 | |
| Quantity manufactured | | Narcotic drug | Quantity consumed | | Quantity utilized for the manufacture of Schedule III preparations | | Quantity held in stocks as at  31 December | | Quantity procured (P) for or withdrawn (W) from special stocks | | | Quantity lost or destroyed*a* | |
| *Kilograms* | *Grams* | *Kilograms* | *Grams* | *Kilograms* | *Grams* | *Kilograms* | *Grams* | *Kilograms* | *Grams* | *P/W* | *Kilograms* | *Grams* |
|  |  | **Alphaprodine** |  |  |  |  |  |  |  |  |  |  |  |
|  |  | **Anileridine** |  |  |  |  |  |  |  |  |  |  |  |
|  |  | **Bezitramide** |  |  |  |  |  |  |  |  |  |  |  |
|  |  | **Cannabis** |  |  |  |  |  |  |  |  |  |  |  |
|  |  | **Cannabis resin** |  |  |  |  |  |  |  |  |  |  |  |
|  |  | **Coca leaf** |  |  |  |  |  |  |  |  |  |  |  |
|  |  | **Cocaine** |  |  |  |  |  |  |  |  |  |  |  |
|  |  | **Codeine** |  |  |  |  |  |  |  |  |  |  |  |
|  |  | **Dextromoramide** |  |  |  |  |  |  |  |  |  |  |  |
|  |  | **Dextropropoxyphene** |  |  |  |  |  |  |  |  |  |  |  |
|  |  | **Difenoxin** |  |  |  |  |  |  |  |  |  |  |  |
|  |  | **Dihydrocodeine** |  |  |  |  |  |  |  |  |  |  |  |
|  |  | **Diphenoxylate** |  |  |  |  |  |  |  |  |  |  |  |
|  |  | **Dipipanone** |  |  |  |  |  |  |  |  |  |  |  |
|  |  | **Ethylmorphine** |  |  |  |  |  |  |  |  |  |  |  |
|  |  | **Heroin** |  |  |  |  |  |  |  |  |  |  |  |
|  |  | **Hydrocodone** |  |  |  |  |  |  |  |  |  |  |  |
|  |  | **Hydromorphone** |  |  |  |  |  |  |  |  |  |  |  |
|  |  | **Ketobemidone** |  |  |  |  |  |  |  |  |  |  |  |
|  |  | **Levorphanol** |  |  |  |  |  |  |  |  |  |  |  |
|  |  | **Methadone** |  |  |  |  |  |  |  |  |  |  |  |

*a* See the instructions on page 3, paragraph 9, “Column 7”.

## PART I.A (*continued*)

## (For all Governments)

Page 6 (Form C)

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1 | | 2 | 3 | | 4 | | 5 | | 6 | | | 7 | |
| Quantity manufactured | | Narcotic drug | Quantity consumed | | Quantity utilized for the manufacture of Schedule III preparations | | Quantity held in stocks as at  31 December | | Quantity procured (P) for or withdrawn (W) from special stocks | | | Quantity lost or destroyed*a* | |
| *Kilograms* | *Grams* | *Kilograms* | *Grams* | *Kilograms* | *Grams* | *Kilograms* | *Grams* | *Kilograms* | *Grams* | *P/W* | *Kilograms* | *Grams* |
|  |  | **Morphine** |  |  |  |  |  |  |  |  |  |  |  |
|  |  | **Nicomorphine** |  |  |  |  |  |  |  |  |  |  |  |
|  |  | **Normethadone** |  |  |  |  |  |  |  |  |  |  |  |
|  |  | **Opium** |  |  |  |  |  |  |  |  |  |  |  |
|  |  | **Oripavine** |  |  |  |  |  |  |  |  |  |  |  |
|  |  | **Oxycodone** |  |  |  |  |  |  |  |  |  |  |  |
|  |  | **Oxymorphone** |  |  |  |  |  |  |  |  |  |  |  |
|  |  | **Pethidine** |  |  |  |  |  |  |  |  |  |  |  |
|  |  | **Phenoperidine** |  |  |  |  |  |  |  |  |  |  |  |
|  |  | **Pholcodine** |  |  |  |  |  |  |  |  |  |  |  |
|  |  | **Thebacon** |  |  |  |  |  |  |  |  |  |  |  |
|  |  | **Thebaine** |  |  |  |  |  |  |  |  |  |  |  |
|  |  | **Tilidine** |  |  |  |  |  |  |  |  |  |  |  |
|  |  | **Trimeperidine** |  |  |  |  |  |  |  |  |  |  |  |
| *Grams* | *Milligrams* |  | *Grams* | *Milligrams* |  | | *Grams* | *Milligrams* | *Grams* | *Milligrams* | *P/W* | *Grams* | *Milligrams* |
|  |  | **Fentanyl** |  |  |  |  |  |  |  |  |  |
|  |  | **Alfentanil** |  |  |  |  |  |  |  |  |  |
|  |  | **Remifentanil** |  |  |  |  |  |  |  |  |  |
|  |  | **Sufentanil** |  |  |  |  |  |  |  |  |  |
|  |  | **Etorphine** |  |  |  |  |  |  |  |  |  |
|  |  | **Piritramide** |  |  |  |  |  |  |  |  |  |

*a* See the instructions on page 3, paragraph 9, “Column 7”.

**PART I.B**

(Only for Governments of countries or territories that utilize concentrate of poppy straw)

Page 7 (Form C)

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1 | 2 | 3 | | 4 | | 5 | | | 6 | |
| Quantity manufactured | Narcotic drug | Quantity consumed | | Quantity held in  stocks as at  31 December | | Quantity procured (P) for or withdrawn (W) from special stocks | | | Quantity lost or destroyed*a* | |
| *Kilograms* | *Kilograms* | *Grams* | *Kilograms* | *Grams* | *Kilograms* | *Grams* | *P/W* | *Kilograms* | *Grams* |
| *b* | **Concentrate of poppy straw (M) GW** | *b* |  | *b* |  | *b* |  |  | *b* |  |
|  | **AMA** | *c* |  | *c* |  | *c* |  |  | *c* |  |
|  | **ACA** | *c* |  | *c* |  | *c* |  |  | *c* |  |
|  | **ATA** | *c* |  | *c* |  | *c* |  |  | *c* |  |
|  | **AOA** | *c* |  | *c* |  | *c* |  |  | *c* |  |
| *b* | **Concentrate of poppy straw (T) GW** | *b* |  | *b* |  | *b* |  |  | *b* |  |
|  | **ATA** | *c* |  | *c* |  | *c* |  |  | *c* |  |
|  | **AMA** | *c* |  | *c* |  | *c* |  |  | *c* |  |
|  | **ACA** | *c* |  | *c* |  | *c* |  |  | *c* |  |
|  | **AOA** | *c* |  | *c* |  | *c* |  |  | *c* |  |
| *b* | **Concentrate of poppy straw (O) GW** | *b* |  | *b* |  | *b* |  |  | *b* |  |
|  | **AOA** | *c* |  | *c* |  | *c* |  |  | *c* |  |
|  | **AMA** | *c* |  | *c* |  | *c* |  |  | *c* |  |
|  | **ACA** | *c* |  | *c* |  | *c* |  |  | *c* |  |
|  | **ATA** | *c* |  | *c* |  | *c* |  |  | *c* |  |
| *b* | **Concentrate of poppy straw (C) GW** | *b* |  | *b* |  | *b* |  |  | *b* |  |
|  | **ACA** | *c* |  | *c* |  | *c* |  |  | *c* |  |
|  | **AMA** | *c* |  | *c* |  | *c* |  |  | *c* |  |
|  | **AOA** | *c* |  | *c* |  | *c* |  |  | *c* |  |
|  | **ATA** | *c* |  | *c* |  | *c* |  |  | *c* |  |

*a* See the instructions on page 3, paragraph 9, “Column 6”.

*b* Quantity to be expressed in gross weight (GW).

*c* Quantity of the anhydrous alkaloid contained in concentrate of poppy straw.

**PART II.A**

(Only for Governments of countries or territories that utilize opiate raw material for the manufacture of narcotic drugs)

| 1 | 2 | | | 3 | 4 | |
| --- | --- | --- | --- | --- | --- | --- |
| Substance used | Quantity used | | | Substance obtained | Quantity obtained | |
| *Kilograms* | *Grams* | | *Kilograms* | *Grams* |
| **Opium** |  |  | | **Morphine** |  |  |
|  |  | | **Codeine** |  |  |
|  |  | | **Thebaine** |  |  |
| **Poppy straw (M)** |  |  | | **Concentrate of poppy straw (M) GW** | *a* |  |
|  | | | **AMA** | *b* |  |
| **ACA** | *b* |  |
| **ATA** | *b* |  |
| **AOA** | *b* |  |
|  | |  | **Morphine** |  |  |
|  | | | **Codeine** |  |  |
| **Thebaine** |  |  |
| **Oripavine** |  |  |
| **Poppy straw (T)** |  | |  | **Concentrate of poppy straw (T) GW** | *a* |  |
|  | | | **ATA** | *b* |  |
| **AMA** | *b* |  |
| **ACA** | *b* |  |
| **AOA** | *b* |  |
|  | |  | **Concentrate of poppy straw (O) GW** | *a* |  |
|  | | | **AOA** | *b* |  |
| **AMA** | *b* |  |
| **ACA** | *b* |  |
| **ATA** | *b* |  |
|  | |  | **Thebaine** |  |  |
| **Poppy straw (C)** |  | |  | **Concentrate of poppy straw (C) GW** | *a* |  |
|  | | | **ACA** | *b* |  |
| **AMA** | *b* |  |
| **AOA** | *b* |  |
| **ATA** | *b* |  |
|  | |  | **Codeine** |  |  |
| ***Papaver bracteatum****c* |  | |  | **Thebaine** |  |  |

*a* Quantity to be expressed in gross weight (GW).

*b* Quantity of the anhydrous alkaloid contained in concentrate of poppy straw.

*c* In its resolution 1982/12, the Economic and Social Council appealed to Governments that had not cultivated *Papaver bracteatum* to consider possibilities for refraining from embarking on the commercial cultivation of *Papaver bracteatum*.

**PART II.A**

(Only for Governments of countries or territories that utilize concentrate of poppy straw for the manufacture of narcotic drugs)

| 1 | 2 | | 3 | 4 | |
| --- | --- | --- | --- | --- | --- |
| Substance used | Quantity used | | Substance obtained | Quantity obtained | |
| *Kilograms* | *Grams* | *Kilograms* | *Grams* |
| **Concentrate of poppy straw (M) GW** | *a* |  |  |  | |
| **AMA** | *b* |  | **Morphine** |  |  |
| **ACA** | *b* |  | **Codeine** |  |  |
| **ATA** | *b* |  | **Thebaine** |  |  |
| **AOA** | *b* |  | **Oripavine** |  |  |
| **Concentrate of poppy straw (T) GW** | *a* |  |  | | |
| **ATA** | *b* |  | **Thebaine** |  |  |
| **AMA** | *b* |  | **Morphine** |  |  |
| **ACA** | *b* |  | **Codeine** |  |  |
| **AOA** | *b* |  | **Oripavine** |  |  |
| **Concentrate of poppy straw (O) GW** | *a* |  |  | | |
| **AOA** | *b* |  | **Oripavine** |  |  |
| **AMA** | *b* |  | **Morphine** |  |  |
| **ACA** | *b* |  | **Codeine** |  |  |
| **ATA** | *b* |  | **Thebaine** |  |  |
| **Concentrate of poppy straw (C) GW** | *a* |  |  | | |
| **ACA** | *b* |  | **Codeine** |  |  |
| **AMA** | *b* |  | **Morphine** |  |  |
| **AOA** | *b* |  | **Oripavine** |  |  |
| **ATA** | *b* |  | **Thebaine** |  |  |
| *Residual water containing alkaloids (please specify origin)* |  |  | **Codeine** |  |  |
|  |  | **Morphine** |  |  |
|  |  | **Oripavine/Thebaine** |  |  |

*a* Quantity to be expressed in gross weight (GW).

*b* Quantity of the anhydrous alkaloid contained in concentrate of poppy straw.

**PART II.B**

(Only for Governments of countries or territories that utilize narcotic drugs for the manufacture of other substances)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| 1 | 2 | | 3 | 4 | |
| Substance used | Quantity used | | Substance obtained | Quantity obtained | |
| *Kilograms* | *Grams* | *Kilograms* | *Grams* |
| **Morphine** |  |  | **Codeine** |  |  |
|  |  | **Ethylmorphine** |  |  |
|  |  | **Heroin** |  |  |
|  |  | **Hydromorphone** |  |  |
|  |  | **Pholcodine** |  |  |
|  |  | **Apomorphine** |  |  |
|  |  | **Nalorphine** |  |  |
|  |  |  |  |  |
| **Oripavine** |  |  | **Hydromorphone** |  |  |
|  |  | **Oxymorphone** |  |  |
|  |  | **Thebaine** |  |  |
|  |  |  |  |  |
| **Thebaine** |  |  | **Codeine** |  |  |
|  |  | **Dihydrocodeine** |  |  |
|  |  | **Hydrocodone** |  |  |
|  |  | **Oxycodone** |  |  |
|  |  | **Thebacon** |  |  |
|  |  | **Buprenorphine** |  |  |
|  |  | **Nalbuphine** |  |  |
|  |  | **Naloxone** |  |  |
|  |  | **Naltrexone** |  |  |
|  |  |  |  |  |
| **Codeine** |  |  | **Dihydrocodeine** |  |  |
|  |  | **Hydrocodone** |  |  |
|  |  |  |  |  |
| **Oxycodone** |  |  | **Oxymorphone** |  |  |
|  |  | **Naloxone** |  |  |
|  |  | **Naltrexone** |  |  |
|  |  |  |  |  |
| **Coca leaf** |  |  | **Cocaine** |  |  |
|  |  | **Coca paste** |  |  |
|  |  | **Ecgonine** |  |  |
| **Coca paste** |  |  | **Cocaine** |  |  |
| **Ecgonine** |  |  | **Cocaine** |  |  |
| **Hydrocodone** |  |  | **Dihydrocodeine** |  |  |
|  |  | **Thebaine** |  |  |
| **Methadone intermediate** |  |  | **Methadone** |  |  |
| **Pethidine intermediate A** |  |  | **Pethidine intermediate B** |  |  |
| **Pethidine intermediate B** |  |  | **Pethidine intermediate C** |  |  |
| **Pethidine intermediate C** |  |  | **Pethidine** |  |  |
| **Racemoramide** |  |  | **Dextromoramide** |  |  |
|  |  | **Levomoramide** |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |

**PART III.A**

(Only for Governments that authorize the cultivation of opium poppy for the production of opium,

and/or the production of poppy straw (M), (T) and (C) and/or for culinary and/or decorative purposes)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Cultivation of opium poppy** | 1 | | 2 | |
| **Area cultivated** | | **Quantity produced** | |
| Sown | Harvested | Opium  (at 90% consistency) | Poppy straw*a* |
| *Hectares* | | *Kilograms* | |
| 1. **For the production of** **opium** |  |  |  |  |
| 2 a. **For the production of**  **poppy straw (M)** for the manufacture of narcotic drugs |  |  |  |  |
| 2 b. **For the production of**  **poppy straw (T)** for the manufacture of narcotic drugs |  |  |  |
| 2 c. **For the production of**  **poppy straw (C)** for the manufacture of narcotic drugs |  |  |  |
| 3. **For purposes other** than the production or manufacture of narcotic drugs |  |  |  |

*a*Requested on a voluntary basis, pursuant to Economic and Social Council resolution 1978/12 and to General Assembly resolution 33/168.

**PART III.B**

(Only for Governments that authorize the cultivation of the cannabis plant and the production of cannabis for medical and/or scientific purposes)

|  |  |  |  |
| --- | --- | --- | --- |
| **Cultivation of the cannabis plant** | 1 | | 2 |
| **Area cultivated** | | **Quantity produced** |
| Sown | Harvested |
| *Hectares* | | *Kilograms* |
| 1a. **For the production of cannabis** *for medical purposes* |  |  |  |
| 1b. **For the production of cannabis** *for scientific purposes* |  |  |  |

**PART III.C**

(Only for Governments that authorize the cultivation of the coca bush and the production of coca leaves)

|  |  |  |  |
| --- | --- | --- | --- |
| **Cultivation of the coca bush** | 1 | | 2 |
| **Area cultivated** | | **Quantity produced** |
| Sown | Harvested |
| *Hectares* | | *Kilograms* |
| 1. **For the production of** **coca leaves** *for the manufacture of cocaine and flavouring agents* |  |  |  |
| 2. **For the production of** **coca leaves** *for the production of flavouring agents only.* |  |  |  |
| 3. **For the production of** **coca leaves for purposes *other*** *than those listed in 1  and 2.* |  |  |  |

**PART IV.A**

**Seizures of narcotic drugs (excluding pharmaceutical products)***a*

(For all Governments)

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | 1 | | 2 | | 3 | | 4 | | 5 | |
| Substance | Quantity seized | | Disposal of seized quantities  *(including those seized in previous years)* | | | | | | Seized quantity not disposed of pending a decision | |
| Quantity destroyed | | Quantity used for licit purposesb | | Quantity taken over by the Government for special purposes | |
|  | *Kilograms* | *Grams* | *Kilograms* | *Grams* | *Kilograms* | *Grams* | *Kilograms* | *Grams* | *Kilograms* | *Grams* |
| **Cannabis** |  |  |  |  |  |  |  |  |  |  |
| **Cannabis resin** |  |  |  |  |  |  |  |  |  |  |
| **Coca leaf** |  |  |  |  |  |  |  |  |  |  |
| **Coca paste** |  |  |  |  |  |  |  |  |  |  |
| **Cocaine** |  |  |  |  |  |  |  |  |  |  |
| **Heroin** |  |  |  |  |  |  |  |  |  |  |
| **Morphine** |  |  |  |  |  |  |  |  |  |  |
| **Opium** |  |  |  |  |  |  |  |  |  |  |
| **Others*****(Specify any other narcotic drug, including synthetic narcotic drugs such as fentanyl and/or its analogues and/or other opioids, etc.)*** | | | | | | | | | | |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |

*a*Quantities to be expressed in gross weight.

*b*Governments that release seized drugs for licit medical and scientific purposes should, in addition to the gross weight of the drug released, also report its pure anhydrous drug content in order to facilitate the monitoring by the International Narcotics Control Board of the consumption and/or utilization of those drugs. This information may be included in   
the space under “Remarks” on page 1 of Form C.

**PART IV.B**

**Seizures of pharmaceutical products containing narcotic drugs**

(For all Governments)

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Substance | Pharmaceutical form and content of active ingredient per unit | | | | | | | | | | |
| 1 | | 2 | | 3 | | 4 | | 5 | | |
| Ampoules | | Capsules | | Patches | | Tablets | | Other forms | | |
| Number of units | Content per unit | Number of units | Content per unit | Number of units | Content per unit | Number of units | Content per unit | Form | Number of units | Content per unit |
| *milligrams* | *milligrams* | *milligrams* | *milligrams* | *milligrams* |
| **Codeine** |  |  |  |  |  |  |  |  |  |  |  |
| **Fentanyl** |  |  |  |  |  |  |  |  |  |  |  |
| **Methadone** |  |  |  |  |  |  |  |  |  |  |  |
| **Morphine** |  |  |  |  |  |  |  |  |  |  |  |
| **Oxycodone** |  |  |  |  |  |  |  |  |  |  |  |
| **Pethidine** |  |  |  |  |  |  |  |  |  |  |  |
| **Others** *(****Specify any other pharmaceutical product containing narcotic drugs such as dihydrocodeine, dextropropoxyphene, hydrocodone, hydromorphone, trimeperidine, etc.)*** | | | | | | | | | | | |
|  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |